MacroGenics Inc (NASDAQ:MGNX) — Market Cap & Net Worth
Market Cap & Net Worth: MacroGenics Inc (MGNX)
MacroGenics Inc (NASDAQ:MGNX) has a market capitalization of $218.65 Million ($218.65 Million) as of June 25, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16261 globally and #3812 in its home market, demonstrating a 18.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MacroGenics Inc's stock price $4.69 by its total outstanding shares 63560068 (63.56 Million). Review MacroGenics Inc (MGNX) total liabilities to assess the company's total debt and financial obligations.
MacroGenics Inc Market Cap History: 2015 to 2026
MacroGenics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.97 Billion to $298.10 Million (-15.75% CAGR).
Index Memberships
MacroGenics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #446 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1600 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.71 Trillion | 0.01% | #223 of 263 |
Weight: MacroGenics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MacroGenics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MacroGenics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.68x
MacroGenics Inc's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.30 Billion | $86.58 Million | -$58.53 Million | 15.01x | N/A |
| 2017 | $1.21 Billion | $155.52 Million | -$19.63 Million | 7.77x | N/A |
| 2018 | $807.21 Million | $60.12 Million | -$171.45 Million | 13.43x | N/A |
| 2019 | $691.53 Million | $62.02 Million | -$151.81 Million | 11.15x | N/A |
| 2020 | $1.45 Billion | $97.76 Million | -$117.78 Million | 14.86x | N/A |
| 2021 | $1.02 Billion | $75.64 Million | -$190.86 Million | 13.49x | N/A |
| 2022 | $426.49 Million | $151.94 Million | -$120.02 Million | 2.81x | N/A |
| 2023 | $611.45 Million | $57.19 Million | -$9.06 Million | 10.69x | N/A |
| 2024 | $206.57 Million | $148.34 Million | -$66.97 Million | 1.39x | N/A |
| 2025 | $102.33 Million | $149.50 Million | -$74.62 Million | 0.68x | N/A |
Competitor Companies of MGNX by Market Capitalization
Companies near MacroGenics Inc in the global market cap rankings as of June 25, 2026.
Key companies related to MacroGenics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #218 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.67 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #218 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $468.42 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.67 Billion | $618.03 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €251.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €813.00 |
MacroGenics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, MacroGenics Inc's market cap moved from $1.97 Billion to $ 298.10 Million, with a yearly change of -15.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $298.10 Million | +191.30% |
| 2025 | $102.33 Million | -50.46% |
| 2024 | $206.57 Million | -66.22% |
| 2023 | $611.45 Million | +43.37% |
| 2022 | $426.49 Million | -58.19% |
| 2021 | $1.02 Billion | -29.79% |
| 2020 | $1.45 Billion | +110.11% |
| 2019 | $691.53 Million | -14.33% |
| 2018 | $807.21 Million | -33.16% |
| 2017 | $1.21 Billion | -7.05% |
| 2016 | $1.30 Billion | -34.00% |
| 2015 | $1.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 24th, 2026 the market cap of MacroGenics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $218.65 Million USD |
| MoneyControl | $218.65 Million USD |
| MarketWatch | $218.65 Million USD |
| marketcap.company | $218.65 Million USD |
| Reuters | $218.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more